Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate. It is an endothelin receptor antagonist. It failed a phase III clinical trial for prostate cancer but other trials are planned. Tolerability of zibotentan plus docetaxel has been evaluated. ... Found on http://en.wikipedia.org/wiki/Zibotentan
A substance being studied in the treatment of some types of cancer. Zibotentan may block cancer cell growth. It is a type of endothelin-A receptor antagonist. Found on http://www.cancer.gov/dictionary?expand=Z